Helka Göös

Helka Göös serves as Principal Investigator and Group Leader of the Immune Cell Therapy of Cancer (iCell) research group at the Finnish Red Cross Blood Service’s (FRCBS) Research and Development unit. The iCell team brings extensive expertise in immune cell therapies, including CAR-T and CAR-NK approaches, and focuses on both academic research and the development of advanced cell therapies.

Their work encompasses the isolation of NK and T cells from peripheral and cord blood, the design of chimeric antigens targeting multiple tumor-associated markers, and sophisticated genetic modifications, such as knock-ins via lentiviral transduction and knock-outs using CRISPR base editing techniques. In addition, the team has developed efficient cell expansion methods and performs comprehensive functional analyses to ensure therapeutic efficacy. The group’s mission is to transform these innovations into clinically applicable therapies through the Advanced Cell Therapy Centre at FRCBS. Helka is one of the PIs in the Research Council of Finland’s Flagship GeneCellNano.